Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Mycobacterial skin and soft tissue infections: TB or not TB?

van Mechelen M, van der Hilst J, Gyssens IC, Messiaen P.

Neth J Med. 2018 Aug;76(6):269-274.

2.

Bone Disease in Axial Spondyloarthritis.

Van Mechelen M, Gulino GR, de Vlam K, Lories R.

Calcif Tissue Int. 2018 May;102(5):547-558. doi: 10.1007/s00223-017-0356-2. Epub 2017 Oct 31. Review.

PMID:
29090349
3.

Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.

Leroux-Roels G, Marchant A, Levy J, Van Damme P, Schwarz TF, Horsmans Y, Jilg W, Kremsner PG, Haelterman E, Clément F, Gabor JJ, Esen M, Hens A, Carletti I, Fissette L, Tavares Da Silva F, Burny W, Janssens M, Moris P, Didierlaurent AM, Van Der Most R, Garçon N, Van Belle P, Van Mechelen M.

Clin Immunol. 2016 Aug;169:16-27. doi: 10.1016/j.clim.2016.05.007. Epub 2016 May 25.

4.

Microtrauma: no longer to be ignored in spondyloarthritis?

Van Mechelen M, Lories RJ.

Curr Opin Rheumatol. 2016 Mar;28(2):176-80. doi: 10.1097/BOR.0000000000000254. Review.

PMID:
26751839
5.

Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.

Leroux-Roels G, Van Belle P, Vandepapeliere P, Horsmans Y, Janssens M, Carletti I, Garçon N, Wettendorff M, Van Mechelen M.

Vaccine. 2015 Feb 18;33(8):1084-91. doi: 10.1016/j.vaccine.2014.10.078. Epub 2014 Nov 7.

6.

Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.

Didierlaurent AM, Collignon C, Bourguignon P, Wouters S, Fierens K, Fochesato M, Dendouga N, Langlet C, Malissen B, Lambrecht BN, Garçon N, Van Mechelen M, Morel S.

J Immunol. 2014 Aug 15;193(4):1920-30. doi: 10.4049/jimmunol.1400948. Epub 2014 Jul 14.

7.

Narcolepsy and A(H1N1)pdm09 vaccination: shaping the research on the observed signal.

van der Most R, Van Mechelen M, Destexhe E, Wettendorff M, Hanon E.

Hum Vaccin Immunother. 2014;10(3):572-6. Epub 2013 Dec 16.

8.

Effects of coffee management intensity on composition, structure, and regeneration status of ethiopian moist evergreen afromontane forests.

Hundera K, Aerts R, Fontaine A, Van Mechelen M, Gijbels P, Honnay O, Muys B.

Environ Manage. 2013 Mar;51(3):801-9. doi: 10.1007/s00267-012-9976-5. Epub 2012 Nov 22.

PMID:
23180249
9.

Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach.

Garçon N, Morel S, Didierlaurent A, Descamps D, Wettendorff M, Van Mechelen M.

BioDrugs. 2011 Aug 1;25(4):217-26. doi: 10.2165/11591760-000000000-00000. Review.

PMID:
21815697
10.

The safety evaluation of adjuvants during vaccine development: the AS04 experience.

Garçon N, Segal L, Tavares F, Van Mechelen M.

Vaccine. 2011 Jun 15;29(27):4453-9. doi: 10.1016/j.vaccine.2011.04.046. Epub 2011 Apr 27. Review.

PMID:
21527299
11.

Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.

Garçon N, Van Mechelen M.

Expert Rev Vaccines. 2011 Apr;10(4):471-86. doi: 10.1586/erv.11.29. Review.

PMID:
21506645
12.

Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile.

Garçon N, Wettendorff M, Van Mechelen M.

Expert Opin Biol Ther. 2011 May;11(5):667-77. doi: 10.1517/14712598.2011.573624. Epub 2011 Apr 4. Review.

PMID:
21457083
13.

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, Kielland A, Chomez P, Garçon N, Van Mechelen M.

Vaccine. 2011 Mar 16;29(13):2461-73. doi: 10.1016/j.vaccine.2011.01.011. Epub 2011 Jan 20.

PMID:
21256188
14.

H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.

Moris P, van der Most R, Leroux-Roels I, Clement F, Dramé M, Hanon E, Leroux-Roels GG, Van Mechelen M.

J Clin Immunol. 2011 Jun;31(3):443-54. doi: 10.1007/s10875-010-9490-6. Epub 2010 Dec 21.

15.

CD14-independent responses induced by a synthetic lipid A mimetic.

Legat A, Thomas S, Hermand P, Van Mechelen M, Goldman M, De Wit D.

Eur J Immunol. 2010 Mar;40(3):797-802. doi: 10.1002/eji.200939992.

16.

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.

Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, Larocque D, Van Mechelen M, Garçon N.

J Immunol. 2009 Nov 15;183(10):6186-97. doi: 10.4049/jimmunol.0901474. Epub 2009 Oct 28.

17.

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G.

Vaccine. 2010 Jan 8;28(3):849-57. doi: 10.1016/j.vaccine.2009.10.017. Epub 2009 Oct 14.

PMID:
19835828
18.

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

Vandepapelière P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, Van Belle P, Clement F, Hanon E, Wettendorff M, Garçon N, Leroux-Roels G.

Vaccine. 2008 Mar 4;26(10):1375-86. doi: 10.1016/j.vaccine.2007.12.038. Epub 2008 Jan 14.

PMID:
18272264
19.

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.

Garçon N, Chomez P, Van Mechelen M.

Expert Rev Vaccines. 2007 Oct;6(5):723-39. Review.

PMID:
17931153
20.

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin MT, Dubin G, Wettendorff MA.

Vaccine. 2006 Aug 14;24(33-34):5937-49. Epub 2006 Jun 19.

PMID:
16828940

Supplemental Content

Loading ...
Support Center